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We have found that ﬂuvoxamine-induced increases in prefrontal dopamine release are enhanced by
adrenalectomy/castration and 5-HT1A receptors are involved in the enhancement. This study examined
which 5-HT1A autoreceptors or postsynaptic receptor play a key role in the enhancement in mice.
Adrenalectomy/castration-induced enhancement of ﬂuvoxamine-induced increase in the dopamine
release was not blocked by local perfusion with the 5-HT1A receptor antagonist WAY100635 (10 mM),
while it was blocked by systemic administration of WAY100635 at low dose (0.1 mg/kg) which blocked
preferentially autoreceptor-mediated responses. These ﬁnding suggests that 5-HT1A autoreceptors play a
key role in the enhancement of prefrontal dopamine release.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.Fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor, is
used for the treatment of major depressive disorders. This drug
shows agonist activity at the s1 receptor (1). Ishikawa et al. re-
ported using positron emission tomography that the s1 receptor is
involved in the clinical effects of ﬂuvoxamine (2), but the details of
this involvement are not known. We have previously found that
ﬂuvoxamine-induced increases in prefrontal dopamine release
are enhanced by adrenalectomy/castration and this effect is
mediated by both 5-HT reuptake inhibition and s1 receptor acti-
vation (3). The ﬁnding implies that prefrontal dopamine release is
regulated by the interaction between the 5-HT system and s1armacology, Graduate School
mada-oka, Suita, Osaka, 565-
8159.
tsuda).
acological Society.
Production and hosting by Elseviereceptor in the conditions of low plasma steroid levels such as
older persons or patients with depression or posttraumatic stress
disorder (4). We subsequently showed that 5-HT1A receptors play
a key role in the synergistic effects of prefrontal dopaminergic
transmission under the conditions of circulating steroid deﬁ-
ciency (4). These ﬁndings suggest that the prefrontal dopami-
nergic system is regulated by an interaction between 5-HT1A and
s1 receptors, but the detailed mechanism for this interaction is
not known. 5-HT1A receptors are considered to be a potential
target molecule for treatment of psychiatric disorders and pain
(5), and they are localized not only in 5-HT-containing neurons as
the autoreceptors but also in other neurons as postsynaptic re-
ceptors (6). The present study examined which 5-HT1A autor-
eceptors or postsynaptic receptors play a key role in the
enhancement of ﬂuvoxamine-induced increases in prefrontal
dopamine release by adrenalectomy/castration in mice.
Male ddY mice (5 weeks old) were housed in groups of 5e6 per
cage (24 cm  17 cm  12 cm) under controlled environmentalr B.V. All rights reserved.
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food and water ad libitum) for at least 1 week before use in the
experiments. Adrenalectomy/castration was performed at 6 weeks
of age, in view of the importance of the developing period in the
expression of psychiatric disorders (7). Procedures involving ani-
mals and their care were conducted according to the Guiding
Principles approved by the Japanese Pharmacological Society. Flu-
voxamine maleate (Abbott Japan Co., Ltd., Tokyo, Japan) and
WAY100635 (Mitsubishi Tanabe Pharma Corp., Yokohama, Japan)
were dissolved in saline (0.9% solution of NaCl) and administered at
10 ml/kg intraperitoneally (i.p.). The doses of WAY100635 used
here were selected by referring to our previous study in which
0.1 mg/kgWAY100635 blocked 5-HT1A autoreceptors preferentially
and 1.0 mg/kg blocked both 5-HT1A autoreceptors and postsynaptic
5-HT1A receptors (8). Probe application of WAY100635 at 10 mM
was performed as previously reported (8). Adrenalectomy, castra-
tion and the treatment after surgery were performed as previously
reported (3,4). Sham-operated mice were treated similarly, except
that the adrenals and testes were not removed. Animals were used
3 weeks after surgery.
Microdialysis experiments in the prefrontal cortex (A þ 1.9 mm,
L  0.5 mm, V  0.8 mm, from the bregma and skull) of freely
moving mice were performed as previously reported (4,9). The
active probe membranes were 3 mm long. Microdialysis samples
(20 ml) were collected every 20 min and injected immediately onto
a high-performance liquid chromatography (HPLC) column for
simultaneous assaying of dopamine, noradrenaline, and 5-HT. The
concentrations of dopamine, noradrenaline, and 5-HT in brain
microdialysates were determined by HPLC with an electrochemical
detector (HTEC-500; Eicom Corp., Kyoto, Japan) as previously re-
ported (3,4,9). After the experiments, Evans Blue dye was micro-
injected through the cannula to histologically verify the position of
the probe, and only data from animals with correct probe place-
ment were used in the analysis. All results are presented as theFig. 1. Effects of local application of WAY100635 on ﬂuvoxamine-induced increases in e
adrenalectomized/castrated (AdX/CX) mice. (A) AdX/CX and sham-operated mice were i.p. i
injected 20 min before ﬂuvoxamine treatment (dotted arrow). The results are expressed as th
mice; yP < 0.05, yyP < 0.01, v.s. the value at 0 min in AdX/CX mice; $P < 0.05, $$P < 0.01, v.s. s
mice were i.p. injected with ﬂuvoxamine at 30 mg/kg (Flv) at 60 min (arrow). WAY100635 a
time indicated by the horizontal bar. Data are expressed as the mean ± SEM of 4e6 mice. *P <
the value at 60 min in WAY-treated mice using TukeyeKramer post-hoc test.mean ± standard error of the mean (S.E.M.). All data were
expressed as a percent of baseline, with 100% deﬁned as the
average of the three fractions collected immediately before drug
administration. The data were analyzed using two-way analysis of
variance (ANOVA) with operation or treatment as the intersubject
factor and repeated measures with time as the intrasubject factor,
followed by the TukeyeKramer post-hoc test. Statistical analyses
were performed using the software package Statview 5.0J for Apple
Macintosh (SAS Institute Inc., Cary, NC, USA). A value of P < 0.05 was
considered statistically signiﬁcant.
Baseline levels of extracellular dopamine, noradrenaline, and
5-HT (not corrected for in vitro probe recovery) in the prefrontal
cortex did not differ signiﬁcantly between sham-operated and
adrenalectomized/castrated mice (analyzed using Student's t-
test). The dopamine levels (mean ± S.E.M.; pg/20 ml) were
0.75 ± 0.09 (sham-operated) and 0.84 ± 0.13 (adrenalectomized/
castrated). The noradrenaline levels were 1.10 ± 0.11 (sham-
operated) and 1.19 ± 0.18 (adrenalectomized/castrated). The 5-HT
levels were 1.47 ± 0.29 (sham-operated) and 1.33 ± 0.22 (adre-
nalectomized/castrated). Systemic administration of ﬂuvoxamine
at 30 mg/kg increased the extracellular levels of dopamine,
noradrenaline, and 5-HT in the prefrontal cortex of sham-operated
and adrenalectomized/castrated mice (Fig. 1A). Fluvoxamine-
induced increases in dopamine levels were signiﬁcantly higher
in adrenalectomized/castrated mice compared with sham-
operated mice (interaction between operation and time:
F9,90 ¼ 4.09, P < 0.001). In contrast, the ﬂuvoxamine-induced in-
creases in noradrenaline (F9,90 ¼ 0.35, P > 0.05) and 5-HT
(F9,90 ¼ 0.20, P > 0.05) levels did not differ between the two
groups. These results are in agreement with the previous ﬁndings
(3,4). Fig. 1B shows the effect of local application of WAY100635 on
the effect of ﬂuvoxamine in adrenalectomized/castrated mice.
Local application of WAY100635 at 10 mM into the cortex did not
affect ﬂuvoxamine-induced increase in the extracellular levels ofxtracellular levels of dopamine, noradrenaline, and 5-HT in the prefrontal cortex of
njected with ﬂuvoxamine at 30 mg/kg (Flv) at 0 min (solid arrow). Saline (Sal) was i.p.
e mean ± S.E.M. of 6 mice. *P < 0.05, **P < 0.01, v.s. the value at 0 min in sham-operated
ham-operated mice at each time point using TukeyeKramer post-hoc test. (B) AdX/CX
t 10 mM (WAY) or saline (Sal) was perfused into the cortex via the dialysis probe for the
0.05, **P < 0.01, v.s. the value at 60 min in saline-treated mice; yP < 0.05, yyP < 0.01, v.s.
Fig. 2. Effects of systemic administration of WAY100635 on ﬂuvoxamine-induced increases in extracellular levels of dopamine, noradrenaline, and 5-HT in the prefrontal cortex of
sham-operated (A) and adrenalectomized/castrated (B) mice. Mice were i.p. injected with ﬂuvoxamine at 30 mg/kg (Flv) at 0 min (solid arrow). Saline (Sal) or WAY100635 (WAY) at
0.1 or 1.0 mg/kg was injected i.p. 20 min before ﬂuvoxamine treatment (dotted arrow). The results are expressed as the mean ± S.E.M. of 5e6 mice. $P < 0.05, $$P < 0.01, v.s. saline-
treated mice at each time point in WAY 0.1 mg/kg-treated mice; #P < 0.05, ##P < 0.01, v.s. saline-treated mice at each time point in WAY 1.0 mg/kg-treated mice using
TukeyeKramer post-hoc test.
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castrated mice. There was no signiﬁcant difference in the main
effect of local application (F1,8 ¼ 1.55, P > 0.05 for dopamine;
F1,8¼ 0.11, P > 0.05 for noradrenaline; F1,8¼ 0.05, P > 0.05 for 5-HT)
or in the interaction between local application and time
(F11,88 ¼ 0.50, P > 0.05 for dopamine; F11,88 ¼ 0.85, P > 0.05 for
noradrenaline; F11,88 ¼ 0.26, P > 0.05 for 5-HT).
Fig. 2 shows the effects of WAY100635 at 0.1 and 1.0 mg/kg on
ﬂuvoxamine-induced increases in prefrontal dopamine, noradren-
aline and 5-HT levels in sham-operated and adrenalectomized/
castrated mice. WAY100635 at both doses signiﬁcantly inhibited
ﬂuvoxamine-induced increases in prefrontal dopamine levels in
adrenalectomized/castrated mice (interaction between treatment
and time: F9,72 ¼ 3.83, P < 0.001 for 0.1 mg/kg; F9,72 ¼ 5.77,
P < 0.0001 for 1.0 mg/kg). The dopamine levels in adrenalecto-
mized/castrated mice treated with WAY100635 were similar to
those in sham-operated mice (F9,81 ¼ 0.41, P > 0.05 for 0.1 mg/kg;
F9,81 ¼ 0.59, P > 0.05 for 1.0 mg/kg). WAY100635 did not affect
dopamine release in sham-operated mice. Concerning the 5-HT
levels, WAY100635 at both doses signiﬁcantly potentiated
ﬂuvoxamine-induced increases in 5-HT levels in sham-operated
(F9,81 ¼ 6.01, P < 0.0001 for the low dose; F9,81 ¼ 5.36, P < 0.0001
for the high dose) and adrenalectomized/castrated (F9,72 ¼ 9.43,
P < 0.0001 for the low dose; F9,72¼ 4.14, P < 0.001 for the high dose)
mice. The effects of the lower dose of WAY100635 were similar to
those of the higher dose. Concerning the noradrenaline levels,
WAY100635 at 1.0 mg/kg, but not 0.1 mg/kg, blocked ﬂuvoxamine-
induced increases in noradrenaline levels in the prefrontal cortex of
sham-operated (F9,81 ¼ 6.99, P < 0.0001 for the high dose;
F9,81 ¼ 0.33, P > 0.05 for the low dose) and adrenalectomized/cas-
trated (F9,72 ¼ 5.68, P < 0.0001 for the high dose; F9,72 ¼ 0.59,
P > 0.05 for the low dose) mice.We have previously found that ﬂuvoxamine-induced increases
in prefrontal dopamine release are enhanced by adrenalectomy/
castration and functional interaction between 5-HT1A and s1 re-
ceptors is responsible for the enhancement (4). Furthermore, we
showed that the s1 receptor localized in the prefrontal cortex is
involved in the enhancement. In view of the previous ﬁnding that
the 5-HT1A receptor agonist MKC-242 increases prefrontal dopa-
mine release and this effect is blocked by local application of
WAY100635 (10), it is possible that the functional interaction be-
tween 5-HT1A and s1 receptors occurs in the prefrontal cortex.
However, the present study shows that ﬂuvoxamine-induced in-
creases in dopamine release are not affected by local application of
WAY100635 at 10 mM into the prefrontal cortex. This suggests that
the 5-HT1A receptor in the prefrontal cortex is not involved in the
enhancement of ﬂuvoxamine-induced increases in prefrontal
dopamine release. These observations suggest that the 5-HT1A re-
ceptor in the prefrontal cortex is involved in dopamine release, but
it does not interact with the s1 receptor responsible for the
enhancement of ﬂuvoxamine-induced increases in dopamine
release.
We also examined the effect of low dose of systemic
WAY100635 on the enhancement of ﬂuvoxamine-induced in-
creases in dopamine release, since the antagonist at low dose
preferentially blocked the 5-HT1A autoreceptor-mediated re-
sponses (8). Dopamine release in adrenalectomized/castrated mice
treated with WAY100635 was similar to that in sham-operated
mice. This indicates that WAY100635 at 0.1 mg/kg blocks the
enhancement of ﬂuvoxamine-induced increases in prefrontal
dopamine release by adrenalectomy/castration. Taken together, it is
likely that the 5-HT1A autoreceptor plays a key role in the
enhancement of ﬂuvoxamine-induced increases in prefrontal
dopamine release by adrenalectomy/castration in mice.
Fig. 3. A possible mechanism for the interaction between the s1 and 5-HT1A receptors
responsible for adrenalectomy/castration-induced enhancement of prefrontal dopa-
mine release. DA: dopamine, PFC: prefrontal cortex, VTA: ventral tegmental area.
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uptake inhibitors increase not only extracellular 5-HT but also
noradrenaline levels in the prefrontal cortex (3,4,11,12), but the
mechanisms are not known. The present study shows that
ﬂuvoxamine-induced increases in prefrontal noradrenaline
release are blocked by a high dose of WAY100635, which an-
tagonizes both pre- and postsynaptic 5-HT1A receptors (8). In this
regard, we previously found that noradrenaline release was
increased by postsynaptic 5-HT1A receptor activation in rat hy-
pothalamus (13). Therefore, it is likely that ﬂuvoxamine-induced
increases in noradrenaline levels are due to an indirect mecha-
nism in response to increases in extracellular 5-HT levels. Con-
cerning 5-HT release, the current study shows that the lower
dose of WAY100635 tested potentiates ﬂuvoxamine-induced in-
creases in prefrontal 5-HT levels, in agreement with the previous
study (14). This ﬁnding also supports the previously presented
idea that WAY100635 has a preferential effect at the 5-HT1A
autoreceptors (8).
In conclusion, the present study suggests that the 5-HT1A
autoreceptors in other brain regions than the prefrontal cortex play
a key role in the enhancement of ﬂuvoxamine-induced increases in
prefrontal dopamine levels by adrenalectomy/castration (Fig. 3).
The 5-HT1A autoreceptor interacts functionally with the s1 receptor
and increases prefrontal dopamine release in neurosteroid-
deﬁcient conditions.
Conﬂicts of interest
The authors have no conﬂict of interest to report.Acknowledgments
This study was supported in part by KAKENHI (23390139 (TM),
25460099 (YA), 26293020 (HH) and 26670122 (HH)), and grants
from the Neuropsychiatry Drug Discovery Consortium (NDDC)
established by Dainippon Sumitomo Pharma Co., Ltd. (Japan) with
Osaka University (TM and HH), the Funding Program for Next
Generation World-Leading Researchers (Grant No. LS081 (HH)),
and the Uehara Memorial Foundation, Japan (HH).
References
(1) Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deﬁcits in mice
are improved by subsequent subchronic administration of ﬂuvoxamine: role
of sigma-1 receptors. Neuropsychopharmacology. 2007;32:514e521.
(2) Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. High
occupancy of sigma-1 receptors in the human brain after single oral admin-
istration of ﬂuvoxamine: a positron emission tomography study using [11C]
SA4503. Biol Psychiatry. 2007;62:878e883.
(3) Ago Y, Yano K, Hiramatsu N, Takuma K, Matsuda T. Fluvoxamine enhances
prefrontal dopaminergic neurotransmission in adrenalectomized/castrated
mice via both 5-HT reuptake inhibition and s1 receptor activation. Psycho-
pharmacology. 2011;217:377e386.
(4) Hiramatsu N, Ago Y, Hasebe S, Nishimura A, Mori K, Takuma K, et al. Syner-
gistic effect of 5-HT1A and s1 receptor activation on prefrontal dopaminergic
transmission under circulating steroid deﬁciency. Neuropharmacology.
2013;75:53e61.
(5) Ago Y, Takuma K, Matsuda T. The potential role of serotonin1A receptors in
post-weaning social isolation-induced abnormal behaviors in rodents.
J Pharmacol Sci. 2014;125:237e241.
(6) Barnes NM, Sharp T. A review of central 5-HT receptors and their function.
Neuropharmacology. 1999;38:1083e1152.
(7) Tseng KY, O'Donnell P. Dopamine modulation of prefrontal cortical in-
terneurons changes during adolescence. Cereb Cortex. 2007;17:1235e1240.
(8) Ago Y, Koyama Y, Baba A, Matsuda T. Regulation by 5-HT1A receptors of the
in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology.
2003;45:1050e1056.
(9) Ago Y, Araki R, Tanaka T, Sasaga A, Nishiyama S, Takuma K, et al. Role of social
encounter-induced activation of prefrontal serotonergic systems in the
abnormal behaviors of isolation-reared mice. Neuropsychopharmacology.
2013;38:1535e1547.
(10) Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, Baba A,
et al. Postsynaptic 5-hydroxytryptamine1A receptor activation increases
in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol. 2000;129:
1028e1034.
(11) Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP.
R-ﬂuoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal
cortex and hypothalamus: an in vivo microdialysis and receptor binding
study. Neuropsychopharmacology. 2002;27:949e959.
(12) David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM. Effects of acute
treatment with paroxetine, citalopram and venlafaxine in vivo on noradren-
aline and serotonin outﬂow: a microdialysis study in Swiss mice. Br J Phar-
macol. 2003;140:1128e1136.
(13) Suzuki M, Matsuda T, Asano S, Somboonthum P, Takuma K, Baba A. Increase of
noradrenaline release in the hypothalamus of freelymoving rat by postsynaptic
5-hydroxytryptamine1A receptor activation. Br J Pharmacol. 1995;115:
703e711.
(14) Dawson LA, Nguyen HQ. Effects of 5-HT1A receptor antagonists on ﬂuoxetine-
induced changes in extracellular serotonin concentrations in rat frontal cor-
tex. Eur J Pharmacol. 1998;345:41e46.
